Ikarugamycin: A Natural Product Inhibitor of Clathrin-Mediated Endocytosis - PubMed (original) (raw)
. 2016 Oct;17(10):1139-49.
doi: 10.1111/tra.12425. Epub 2016 Aug 8.
Affiliations
- PMID: 27392092
- PMCID: PMC5260662
- DOI: 10.1111/tra.12425
Ikarugamycin: A Natural Product Inhibitor of Clathrin-Mediated Endocytosis
Sarah R Elkin et al. Traffic. 2016 Oct.
Abstract
Ikarugamycin (IKA) is a previously discovered antibiotic, which has been shown to inhibit the uptake of oxidized low-density lipoproteins in macrophages. Furthermore, several groups have previously used IKA to inhibit clathrin-mediated endocytosis (CME) in plant cell lines. However, detailed characterization of IKA has yet to be performed. Consequently, we performed biochemistry and microscopy experiments to further characterize the effects of IKA on CME. We show that IKA has an IC50 of 2.7 μm in H1299 cells and acutely inhibits CME, but not other endocytic pathways, in a panel of cell lines. Although long-term incubation with IKA has cytotoxic effects, the short-term inhibitory effects on CME are reversible. Thus, IKA can be a useful tool for probing routes of endocytic trafficking.
Keywords: IC50; caveolae-mediated endocytosis; clathrin-independent endocytosis; mammalian cells.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflicts of interests.
Figures
Figure 1. Ikarugamycin inhibits clathrin-mediated endocytosis
A) A semi-log plot of the effect of increasing concentrations of IKA on TfnR uptake in H1299 cells. IKA has an IC50 value of 2.7 µ
m
± 0.3. B) Effect of IKA on Tfn uptake in several different cell lines. The indicated cells were preincubated with 4 µ
m
IKA before uptake of TfnR was measured. Results are reported as amount of TfnR internalized after 5 min at 37°C as a % of untreated control cells. C) Under the same conditions as (B) IKA inhibits uptake of several CME specific receptors: TfnR (H1299), EGFR (H1299) and LDLR (ARPE-19). All experiments represent (n = 3, avg. ± SD).
Figure 2. Ikarugamycin is selective for CME
The effect of increasing concentrations of IKA on caveolae-mediated endocytosis (●), using albumin as ligand, clathrin-independent endocytosis using either CD44 (▲) or CD59 (■) as markers, or clathrin-mediated endocytosis using TfnR (□) as marker in H1299 cells pretreated for 3 h. Data are normalized to the extent of internalization after 5 min in control cells, which was 69 ± 24% for albumin, 23 ± 13% for CD44, 27 ± 16% for CD59 and 109 ± 28% for TfnR control. Two-tailed Student’s _t_-test were used to assess statistical significance. **p < 0.005; (n = 3, avg. ± SD).
Figure 3. Ikarugamycin inhibition of CME is rapid and partially reversible
A) H1299 cells were pretreated with 4 µ
m
IKA for increasing time and inhibition of TfnR uptake in the continuous presence of IKA was compared with control. B) Increasing concentrations of IKA were added without preincubation and TfnR uptake was measured after 5 min H1299 cells after 5 min in the continuous presence of IKA. C) H1299 cells were pretreated with 4 µ
m
IKA for increasing time periods then IKA was washed out for either 30 or 180 min. TfnR uptake was then measured and compared with control (no IKA treatment). All experiments represent (n = 3, avg. ± SD).
Figure 4. Ikarugamycin disrupts clathrin coated pit distributions
A) Immunofluorescence of control/untreated ARPE-19 cells or cells pretreated with 4 µ
m
IKA for 3 h probed with antibodies to CLC and AP2. B) Fractionation of ARPE-19 cells pretreated with 4 µ
m
IKA for 3 h or no pretreatment (control) probed for clathrin heavy chain (CHC) and AP1 and AP2, respectively. The cytosolic (C) fraction was diluted 4× compared with the membrane (M) fraction for western blotting. Na+/K+ ATPase and GAPDH were used as positive and negative controls respectively. C and D) Quantification of CHC and AP2 in membrane versus cytosolic fractions, respectively, plotted on a log scale as percent of total. Two-tailed Student’s _t_-test were used to assess statistical significance. *p < 0.05; **p < 0.005; ***p < 0.0005. All experiments represent (n = 3, avg. ± SD). E) Kymographs from time-lapse images of CLC in either ARPE-19 cells pretreated with 4 µ
m
IKA for 3 h or no pretreatment (control). Kymographs are 450 seconds and span 130 µm.
Figure 5. Ikarugamycin alters Golgi morphology
A) Immunofluorescence of ARPE-19 stably expressing eGFP-CLC either pretreated or not (control) with 4 µ
m
IKA for 3 h and probed with antibodies to adaptor protein 1 (AP1) and GM130. Scale bar = 25 µm. B) Electron microscopy (EM) images of either control or IKA treated cells. White arrows point to the Golgi in each condition. Scale bar = 0.5 µm.
Figure 6. The effect of ikarugamycin on cell viability
ARPE-19, HeLa and H1299 cells were treated with A) 4 µ
m
or B) 32 µ
m
IKA for increasing periods of time followed by measuring cell viability. All experiments represent (n = 3, avg. ± SD).
Figure 7. Ikarugamycin inhibition of CME is rapid and partially reversible at high concentrations
A) ARPE-19 cells or B) H1299 cells were pretreated with 10 µ
m
IKA for 15 min then IKA was either washed out for 3 h or not. TfnR uptake was then measured and compared with control (no IKA treatment). C) ARPE-19 or D) H1299 cells were treated with 10 µ
m
IKA for 15 min then IKA was washed out for 3 h or not followed by measuring cell viability. Two-tailed Student’s _t_-tests were used to assess statistical significance. *p < 0.05; **p < 0.005; ***p < 0.0005. All experiments represent (n = 3, avg. ± SD).
Similar articles
- Selectivity of commonly used inhibitors of clathrin-mediated and caveolae-dependent endocytosis of G protein-coupled receptors.
Guo S, Zhang X, Zheng M, Zhang X, Min C, Wang Z, Cheon SH, Oak MH, Nah SY, Kim KM. Guo S, et al. Biochim Biophys Acta. 2015 Oct;1848(10 Pt A):2101-10. doi: 10.1016/j.bbamem.2015.05.024. Epub 2015 Jun 6. Biochim Biophys Acta. 2015. PMID: 26055893 - Clathrin-independent endocytosis contributes to uptake of glucose into BY-2 protoplasts.
Bandmann V, Homann U. Bandmann V, et al. Plant J. 2012 May;70(4):578-84. doi: 10.1111/j.1365-313X.2011.04892.x. Epub 2012 Feb 16. Plant J. 2012. PMID: 22211449 - Clathrin-dependent and independent endocytic pathways in tobacco protoplasts revealed by labelling with charged nanogold.
Onelli E, Prescianotto-Baschong C, Caccianiga M, Moscatelli A. Onelli E, et al. J Exp Bot. 2008;59(11):3051-68. doi: 10.1093/jxb/ern154. Epub 2008 Jul 4. J Exp Bot. 2008. PMID: 18603619 Free PMC article. - Budding and braking news about clathrin-mediated endocytosis.
Baisa GA, Mayers JR, Bednarek SY. Baisa GA, et al. Curr Opin Plant Biol. 2013 Dec;16(6):718-25. doi: 10.1016/j.pbi.2013.09.005. Epub 2013 Oct 15. Curr Opin Plant Biol. 2013. PMID: 24139529 Review. - Focusing on clathrin-mediated endocytosis.
Rappoport JZ. Rappoport JZ. Biochem J. 2008 Jun 15;412(3):415-23. doi: 10.1042/BJ20080474. Biochem J. 2008. PMID: 18498251 Review.
Cited by
- The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer.
Curcio C, Brugiapaglia S, Bulfamante S, Follia L, Cappello P, Novelli F. Curcio C, et al. Molecules. 2021 Mar 15;26(6):1642. doi: 10.3390/molecules26061642. Molecules. 2021. PMID: 33804240 Free PMC article. Review. - Role of Clathrin and Dynamin in Clathrin Mediated Endocytosis/Synaptic Vesicle Recycling and Implications in Neurological Diseases.
Prichard KL, O'Brien NS, Murcia SR, Baker JR, McCluskey A. Prichard KL, et al. Front Cell Neurosci. 2022 Jan 18;15:754110. doi: 10.3389/fncel.2021.754110. eCollection 2021. Front Cell Neurosci. 2022. PMID: 35115907 Free PMC article. Review. - Insight into the role of clathrin-mediated endocytosis inhibitors in SARS-CoV-2 infection.
Alkafaas SS, Abdallah AM, Ghosh S, Loutfy SA, Elkafas SS, Abdel Fattah NF, Hessien M. Alkafaas SS, et al. Rev Med Virol. 2023 Jan;33(1):e2403. doi: 10.1002/rmv.2403. Epub 2022 Nov 7. Rev Med Virol. 2023. PMID: 36345157 Free PMC article. Review. - Nanoparticle cellular internalization is not required for RNA delivery to mature plant leaves.
Zhang H, Goh NS, Wang JW, Pinals RL, González-Grandío E, Demirer GS, Butrus S, Fakra SC, Del Rio Flores A, Zhai R, Zhao B, Park SJ, Landry MP. Zhang H, et al. Nat Nanotechnol. 2022 Feb;17(2):197-205. doi: 10.1038/s41565-021-01018-8. Epub 2021 Nov 22. Nat Nanotechnol. 2022. PMID: 34811553 Free PMC article. - Disruption of endocytosis through chemical inhibition of clathrin heavy chain function.
Dejonghe W, Sharma I, Denoo B, De Munck S, Lu Q, Mishev K, Bulut H, Mylle E, De Rycke R, Vasileva M, Savatin DV, Nerinckx W, Staes A, Drozdzecki A, Audenaert D, Yperman K, Madder A, Friml J, Van Damme D, Gevaert K, Haucke V, Savvides SN, Winne J, Russinova E. Dejonghe W, et al. Nat Chem Biol. 2019 Jun;15(6):641-649. doi: 10.1038/s41589-019-0262-1. Epub 2019 Apr 22. Nat Chem Biol. 2019. PMID: 31011214 Free PMC article.
References
- Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature. 2003;422:37–44. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 GM042455/GM/NIGMS NIH HHS/United States
- R01 MH061345/MH/NIMH NIH HHS/United States
- R37 MH061345/MH/NIMH NIH HHS/United States
- T32 GM007062/GM/NIGMS NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources